For: | Arriola-Montenegro J, Beas R, Cerna-Viacava R, Chaponan-Lavalle A, Hernandez Randich K, Chambergo-Michilot D, Flores Sanga H, Mutirangura P. Therapies for patients with coexisting heart failure with reduced ejection fraction and non-alcoholic fatty liver disease. World J Cardiol 2023; 15(7): 328-341 [PMID: PMC10415861 DOI: 10.4330/wjc.v15.i7.328] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v15/i7/328.htm |
Number | Citing Articles |
1 |
Yusuke Hirao, Clarke Morihara, Tomoki Sempokuya. Kill two birds with one stone: Hapatologist’s approach to metabolic dysfunction-associated steatotic liver disease and heart failure. World Journal of Cardiology 2024; 16(11): 660-664 doi: 10.4330/wjc.v16.i11.660
|
2 |
Darshan Hullon, Ghasaq K. Subeh, Yelizaveta Volkova, Karolina Janiec, Adam Trach, Ruslan Mnevets. The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF). Cardiovascular Diabetology 2025; 24(1) doi: 10.1186/s12933-025-02607-w
|
3 |
Diana Carina Iovanovici, Bombonica Gabriela Dogaru, Carmen Delia Nistor – Cseppento, Anamaria Lavinia Purza, Cristina Aur, Diana Mocuta, Tapan Behl, Simona Gabriela Bungau. Benefits of sacubitril/valsartan administration and physical training in cardiac rehabilitation: current trends and bibliometric analysis of the years 2015-2024. Balneo and PRM Research Journal 2024; 15(Vol.15, no. 2): 683 doi: 10.12680/balneo.2024.683
|